Kinnate Biopharma Inc. Common Stock
KNTE
KNTE was delisted on the 2nd of April, 2024.
0 hedge funds and large institutions have $0 invested in Kinnate Biopharma Inc. Common Stock in 2024 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 56 closing their positions.
100% less funds holding
Funds holding: 56 → 0 (-56)
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
100% less capital invested
Capital invested by funds: $92.2M → $0 (-$92.2M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 56
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCMI
Foresite Capital Management IV
Larkspur,
California
|
-$25.7M |
| 2 |
O
OrbiMed
New York
|
-$21.3M |
| 3 |
FCMV
Foresite Capital Management V
Larkspur,
California
|
-$9.38M |
| 4 |
LCM
Lynx1 Capital Management
San Juan,
Puerto Rico
|
-$5.27M |
| 5 |
Viking Global Investors
Stamford,
Connecticut
|
-$4.84M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CFM
51
Catalyst Funds Management
Sydney NSW,
Australia
| – | -$4.18K | -1,570 | Closed |
|
|
TRCT
52
Tower Research Capital (TRC)
New York
| – | -$2.9K | -1,091 | Closed |
|
53
UBS Group
Zurich,
Switzerland
| – | -$2.18K | -818 | Closed |
|
|
CL
54
CSS LLC
Chicago,
Illinois
| – | -$1.55K | -584 | Closed |
|
55
Wells Fargo
San Francisco,
California
| – | -$383 | -144 | Closed |
|
KNTE Hedge Fund Activity: Q2 2024 in Review
0 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Kinnate Biopharma Inc. Common Stock (KNTE) for Q2 2024, worth a combined $0 — down 100% from $92.2M a quarter earlier.
Sellers outnumbered buyers: 56 funds closed out of KNTE and 0 opened new positions — a net loss of 56 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Foresite Capital Management IV, exiting entirely with an estimated $25.7M sold.
- 0 institutional investors held Kinnate Biopharma Inc. Common Stock (KNTE) as of Q2 2024, down from 56 in Q1 2024.
- Funds reported $0 of Kinnate Biopharma Inc. Common Stock stock for Q2 2024, down 100% quarter-over-quarter.
- 0 funds opened new Kinnate Biopharma Inc. Common Stock positions in Q2 2024 and 56 closed out, a net change of -56 holders.
- The largest Kinnate Biopharma Inc. Common Stock seller in Q2 2024 was Foresite Capital Management IV, an estimated $25.7M sold.
Based on aggregated 13F filings for Q2 2024.